Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tricaprilin (AC-SD-03) in APOE4-negative Mild to Moderate Alzheimer's Disease
NCT04187547Phase 3Withdrawn
- Sponsor
- Cerecin
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of tricaprilin in Alzheimer's disease (AD), sponsored by Cerecin. Planned start Jun 2022; status: withdrawn.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04187547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187547.